tirzepatide compound lawsuit update Compounders lose battle over Eli Lilly weight loss drug and FDA shortage list Lilly asks to join lawsuit

In our clinical experience at Rivas, tirzepatide patients lose weight faster, plateau less often, and are less likely to stop treatment due to side effects

In the SURMOUNT-1 clinical trial, participants on the highest dose achieved 22.5% body weight reduction over 72 weeks

For the mechanism-level breakdown of how compounded differs from Zepbound and Mounjaro, see our compounded vs brand-name tirzepatide guide

Update on FDAs ongoing evaluation of reports of suicidal thoughts-or-actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

The beyond-use date (BUD) is assigned per lot and is displayed on the dispensed label

Cant find the medicine you need